Cover Image

Sutureless Scleral Tunnel Trabeculectomy Using Adjunctive Topical Bevacizumab: a Clinical Trial

Mohammad Arish, Omid Bagherzadeh, Seyed Sajad Ahmadi, Javad Sadeghi Allah Abadi, Samira Hassanzadeh

Abstract


This study was performed to assess the short term effect of sutureless scleral tunnel trabeculectomy procedure with and without topical bevacizumab.

Thirty patients with primary open-angle glaucoma were enrolled and randomly divided into two groups. Patients in the first group (15 patients) underwent sutureless trabeculectomy without topical bevacizumab and patients in second group (15 patients) underwent sutureless trabeculectomy procedure with 1.25 mg of topical bevacizumab. Intraocular pressure (IOP) of both groups was measured before and 6 months post- operatively. Data were collected and the results were compared between two groups.

Out of the 30 patients in this study, 6 females (40%) and 9 males (60%) underwent sutureless trabeculectomy procedure (group A). Seven females (46.7%) and 8 males (53.3%) underwent sutureless trabeculectomy with topical bevacizumab (group B). Mean age of patients was not significantly different between two groups (p=0.91). A statistical significant difference in time variation of IOP was found between two groups (P<0.001). Mean IOP was 18.4± 4.35 mmHg in sutureless group without bevacizumab and 11.73± 2.12 mmHg in sutureless group with bevacizumab, 6 months post-surgically. No statistical significant difference was found in the baseline IOP between two groups (p=0.28). But IOP changed significantly in group A and B from baseline to 6 months post- operatively (p=0.004 and p<0.001 respectively).

According to our findings, sutureless trabeculectomy procedure is an effective surgical method for reduction of IOP. When a single dose of 1.25 mg topical bevacizumab is added, it is more effective in reduction of IOP compared to the sutureless trabeculectomy alone.




Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.